Study Of The Expression Of PAX2 And AIB-1 In The Malignant Tissues Of Breast And The Relationship Between Theri Expression And The Clinical Pathological Characteristics

Objective:Nowadays,the incidence of breast cancer has become the first killer in malignant tumor of women which seriously threatened the healthy of the vast women and also has a rising trend in recent years.With the increasing incidence of breast cancer, the research on associated genes has become a hot point for curing breast cancer. Studies have shown that PAX2 (Paired box gene 2) and AIB-1 (Amplified in breast cancer-1) involved in the regulation of C-erbB-2 (human epidermal growth factor receptor, HER-2/C-erbB-2) of the transcription machinery in the estrogen receptor ER (estrogen receptor, ER) positive breast cancer patients,further regulation of C-erbB-2 expression.To dates,there was few studies on PAX2, AIB-1 and clinical pathological characteristics of breast cancer and their relationship with C-erbB-2.We detected the expression of PAX2 and AIB-1 in the normal breast tissues and the tumor tissues on the transcriptional and protein level by using reverse transcription-polymerase chain reaction and streptavidin peroxidase conjugated method.Our experiments study the relatetionship between PAX2 and AIB-1 expression in breast cancer and the clinical pathological characteristics and the relatetionship between ER,PR and C-erbB-2 in the breast cancer patients with ER-positive, and provide a new indicators to determine the prognosis of breast cancer and gene therapy.Methods:Detect the expression and interaction of PAX2和AIB-1 in the normal breast tissues and tumor tissues on both transcriptional and protein level by using reverse transcription-polymerase chain reaction and streptavidin peroxidase conjugated method.The relationship between the expression of PAX2 and AIB-1 and the clinical pathological characteristics including age, menses, tumor size, clinical stages, histology grades, pathological type, the metastatic state of the axillary lymph nodes, estrogen receptor,progestogen receptor,C-erbB-2of all the breast cancer patients were analyzed.Results:1 Expression of PAX2 on the mRNA levelThe correction value(PAX2/GAPDH)in the tumor tissues and normal breast tissues were 1.1837±0.4931,1.1778±0.5216.There was no obvious difference of the two groups after statistical analysis(Z=-0.182,p=0.826).1.1 The analysis of PAX2 expression and the relationship of clinical-pathological characteristics on mRNA level.1.1.1 The ages of the patients were analyzed.In 32 cases of breast cancer patients younger than 50, the correction values of PAX2 expression (PAX2/GAPDH) was 1.2148±0.5376;In 36 cases of breast cancer patients oldder than 50, the correction values of PAX2 expression (PAX2/GAPDH) was 1.1742±0.5012. There was no obvious difference in the distribution of ages after statistical analysis(Z=-1.032;p=0.314). Expression of PAX2 had no relationship with the distribution of age.1.1.2 The menstrual condition of the patients were analyzed.In 34 cases of pre-menopause patients, the correction values of PAX2 expression (PAX2/GAPDH) was 1.3163±0.5149;In 34 cases of post-menopause patients, the correction values of PAX2 expression (PAX2/GAPDH) was 1.1691±0.49 88. There was no obvious difference in the distribution of menstrual condition after statistical analysis(Z=-1.325;p=0.125). Expression of PAX2 had no relationship with the distribution of menstrual condition.1.1.3 The tumor size of the patients were analyzed.In 41 cases of patients in T<2cm group, the correction values of PAX2 expression (PAX2/GAPDH) was1.1952±0.4218;In 27 cases of patients in T>2cm group, the correction values of PAX2 expression (PAX2/GAPDH) was 1.1736±0.3994. There was no obvious difference in the distribution of tumor size after statistical analysis(Z=-1.830;p=0.061). Expression of PAX2 had no relationship with the distribution of tumor size.1.1.4 The clinical stage of the patients were analyzed.In 19 cases of patients in stageⅠ,the correction values of PAX2 expression (PAX2/GAPDH) was 1.1559±0.4638;In 33 cases of patients in stageⅡ, the correction values of PAX2 expression (PAX2/GAPDH) was 1.2483±0.4739;In 16 cases of patients in stageⅢ, the correction values of PAX2 expression (PAX2/GAPDH) was 1.2375±0.4214..There was no obvious difference in the distribution of clinical stage after statistical analysis (p=0.593).Expression of PAX2 had no relation-ship with the clinical stages.1.1.5 The histological grade of the patients were analyzed.In 58 cases of patients in histological gradeⅠ～Ⅱ, the correction values of PAX2 expression (PAX2/GAPDH) was 1.4768±0.5129;In 10 cases of patients in histological gradeⅢ, the correction values of PAX2 expression (PAX2/GAPDH) was 1.1543±0.4892There was no obvious difference in the distribution of histological grade after statistical analysis(Z=-1.792;p=0.079). Expression of PAX2 had no relationship with the histological grades.1.1.6 The metastatic state of the axillary lymph nodes of the patients were analyzed.In 25 cases of patients in negative group, the correction values of PAX2 expression (PAX2/GAPDH) was 1.1632±0.5201;In 27 cases of patients in N+≤3 group, the correction values of PAX2 expression (PAX2/GAPDH) was 1.2318±0.5201;In 16 cases of patients in N+>3 group, the correction values of PAX2 expression (PAX2/GAPDH) was 1.5392±0.4983.There was no obvious difference in the distribution of metastatic state of the axillary lymph nodes after statistical analysis (p=0.185).Expression of PAX2 had no relationship with the metastatic state of the axillary lymph nodes.1.1.7 The pathological type of the patients were analyzed.In 56 cases of patients in invasive ductal carcinoma, the correction values of PAX2 expression (PAX2/GAPDH) was 1.3423±0.3831;In 7 cases of patients in invasive lobular carcinoma, the correction values of PAX2 expression (PAX2/GAPDH) was 1.3258±0.4283;In 5 cases of patients in other types, the correction values of PAX2 expression (PAX2/GAPDH) was 1.1682±0.3996. There was no obvious difference in the distribution of pathological type after statistical analysis (p=0.753).Expression of PAX2 had no relationship with the pathological type.1.2 The relationships between expression of PAX2 and C-erbB-2,ER,PR on mRNA level1.2.1 The expression of C-erbB-2 protein was analysed.In 18 cases of patients in C-erbB-2 (-) group, the correction values of PAX2 expression (PAX2/GAPDH) was 1.3867±0.3987;In 31 cases of patients in C-erbB-2(+)-(++) group, the correction values of PAX2 expression (PAX2/GAPDH) was 1.2274±0.4153;In 19 cases of patients in C-erbB-2 (+++) group, the correction values of PAX2 expression (PAX2/GAPDH) was 1.1682±0.3921.There was obvious difference in the distribution of the expression of C-erbB-2 protein after statistical analysis (p=0.037).Further studies show that there were obvious differences among the groups (Z=-2.094,p=0.026;Z=-2.313,p=0.010; Z=-1.913,p=0.039),Expression of PAX2 had negative correlation with the expression of C-erbB-2 protein.1.2.2 The expression of ER protein was analysed.In 32 cases of patients in ER(+)-(++)group, the correction values of PAX2 expression(PAX2/GAPDH) was 1.4212±0.5278;In 36 cases of patients in ER(+++) group, the correction values of PAX2 expression (PAX2/GAPDH) was 1.1275±0.5439.There was no obvious difference in the distribution of the expression of ER protein after statistical analysis (Z=-1.684;p=0.093).Expression of PAX2 had no relationship with the expression of ER protein.1.2.3 The expression of PR protein was analysed.In 44 cases of patients in PR(-)-(++)group, the correction values of PAX2 expression (PAX2/GAPDH) was 1.2692±0.5382;In 24 cases of patients in PR(+++) group, the correction values of PAX2 expression (PAX2/GAPDH) was 1.1684±0.3675.There was no obvious difference in the distribution of the expression of PR protein after statistical analysis (Z=-1.247; p=0.216).Expression of PAX2 had no relationship with the expression of PR protein.2 The analysis of PAX2 expression on protein level.2.1 The analysis of PAX2 expression and the relationship of clinical-pathological characteristics on protein level. 2.1.1 The ages of the patients were analyzed.According to the analysis on the ages of the patients,PAX2 was hyper-expressed in 6 of 32 patients below 50(18.75%),13 of 36 were hyper-expressed in the patients above 50(36.11%). There was no obvious difference in the distribution of ages after statistical analysis(χ2=2.536;p=0.111). Expression of PAX2 had no relationship with the distribution of age.2.1.2 The menstrual condition of the patients were analyzed.According to the menstrual condition of the patients,PAX2 was hyper-expressed in 6 of 34 pre-menopause patients(17.64%),13 of 34 were hyper-expressed in post-menopause patients(38.24%). There was no obvious difference in the distribution of menstrual condition after statistical analysis(χ2=3.579;p=0.059). Expression of PAX2 had no relationship with the distribution of menstrual co-ndition.2.1.3 The tumor size of the patients were analyzed.According to the tumor size of the patients,PAX2 was hyper-expressed in 11 of 41 patients in T≤2cm group(26.83%),8 of 27 were hyper-expressed in T>2cm group (29.62%). There was no obvious difference in the distribution of tumor size after statistical analysis(χ2=0.332;p=0.565).Expression of PAX2 had no relationship with the tumor size.2.1.4 The clinical stage of the patients were analyzed.According to analysis on the clinical stage,PAX2 was hyper-expressed in 3 of 19 patients in stageⅠ(15.79%),10 of 33 patients in stageⅡ(30.30%),6 of 16 patients in stageⅢ(37.50%).There was no obvious difference in the distribution of clinical stage after statistical analysis (χ2=2.337;p=0.311).Expression of PAX2 had no relationship with the clinical stages.2.1.5 The histological grade of the patients were analyzed.According to the analysis on the histological grades,PAX2 was hyper-expressed in 15 of 58 patients in histological gradeⅠ～Ⅱ(25.86%),and was hyper-expressed in 4 of 10 patients in histological gradeⅢ(40.00%).There was no obvious difference in the distribution of histological grade after statistical analysis(χ2=0.290; p=0.590).Expression of PAX2 had no relationship with the histological grades. 2.1.6 The metastatic state of the axillary lymph nodes of the patients were analyzed.According to the analysis on the metastatic state of the axillary lymph nodes,PAX2 was hyper-expressed in 7 of 25 patients in negative group (28.00%),and was hyper-expressed in 6 of 27 patients in N+<3 group (22.22%),6 of 16 patients in N+>3 group (37.50%) PAX2 was hyper-expressed.There was no obvious difference in the distribution of metastatic state of the axillary lymph nodes after statistical analysis (x2=1.144;p=0.564). Expression of PAX2 had no relationship with the metastatic state of the axillary lymph nodes.2.1.7 The pathological type of the patients were analyzed.According to the analysis on the pathological type,PAX2 was hyper-expressed in 16 of 56 patients in invasive ductal carcinoma (28.57%),and was hyper-expressed in 2 of 7 patients in invasive lobular carcinoma (28.57%), while in 1 of 5 patients in other types (20.00%) PAX2 was hyper-expressed.There was no obvious difference in the distribution of pathological type after statistical analysis (χ2=0.180;p=0.914).Expression of PAX2 had no relationship with the pathological type.2.2 The relationships between expression of PAX2 and C-erbB-2,ER,PR on protein level2.2.1 The expression of C-erbB-2 protein was analysed.According to the analysis on the expression of C-erbB-2 protein,PAX2 was hyper-expressed in 9 of 18 patients in C-erbB-2(-) group (50.00%),and was hyper-expressed in 7 of 31 patients in C-erbB-2(+)-(++) group (22.56%), while 3 of 19 patients in C-erbB-2 (+++) group (15.79%)PAX2 was hyper-expressed.There was obvious difference in the distribution of the expression of C-erbB-2 protein after statistical analysis (χ2=6.186;p=0.045).Expression of PAX2 had negative correlation with the expression of C-erbB-2 protein.2.2.2 The expression of ER protein was analysed.According to the analysis on the expression of ER protein,PAX2 was hyper-expressed in 8 of 32 patients in ER(+)-(++) group(25.00%),and was hyper-expressed in 11 of 36 patients in ER(+++)group(30.56%).There was no obvious difference in the distribution of the expression of ER protein after statistical analysis(χ2=0.260;p=0.610). Expression of PAX2 had no relationship with the expression of ER protein.2.2.3 The expression of PR protein was analysed.According to the analysis on the expression of PR protein,PAX2 was hyper-expressed in 12 of 44 patients in PR(-)-(++) group(27.27%),and was hyper-expressed in 7 of 24 patients in PR(+++)group(29.17%).There was no obvious difference in the distribution of the expression of PR protein after statistical analysis(χ2=0.028;p=0.868). Expression of PAX2 had no relationship with the expression of PR protein. 3 Expression of AIB-1 on the mRNA levelThe correction value(AIB-1/GAPDH)in the tumor tissues and normal breast tissues were 1.7385±0.7691,1.2734±0.6840.There was obvious difference of the two groups after statistical analysis (Z=-2.012,p=0.031).The expression of AIB-1 in the tumor tissues were higher than that of the normal breast tissues.3.1 The analysis of AIB-1 expression and the relationship of clinical-pathological characteristics on mRNA level.3.1.1 The ages of the patients were analyzed.In 32 cases of breast cancer patients younger than 50, the correction values of AIB-1 expression (AIB-1/GAPDH) was 1.4628±0.6428;In 36 cases of breast cancer patients oldder than 50, the correction values of AIB-1 expression (AIB-1/GAPDH) was 1.8281±0.5821. There was no obvious difference in the distribution of ages after statistical analysis(Z=-1.801;p=0.074). Expression of AIB-1 had no relationship with the distribution of age.3.1.2 The menstrual condition of the patients were analyzed.In 34 cases of pre-menopause patients, the correction values of AIB-1 expression (AIB-1/GAPDH) was 1.8346±0.8103;In 34 cases of post-menopause patients, the correction values of AIB-1 expression(AIB-1/GAPDH) was 1.7127±0.7935. There was no obvious difference in the distribution of menstrual condition after statistical analysis(Z=-1.846;p=0.058).Expression of AIB-1 had no relationship with the distribution of menstrual condition.3.1.3 The tumor size of the patients were analyzed.In 41 cases of patients in T<2cm group, the correction values of AIB-1 expression (AIB-1/GAPDH) was 1.6869±0.5893;In 27 cases of patients in T>2cm group, the correction values of AIB-1 expression (AIB-1/GAPDH) was 1.7832±0.5082. There was no obvious difference in the distribution of tumor size after statistical analysis(Z=-0.734;p=0.618). Expression of AIB-1 had no relationship with the distribution of tumor size.3.1.4 The clinical stage of the patients were analyzed.In 19 cases of patients in stage I, the correction values of AIB-1 expression (AIB-1/GAPDH) was 1.5428±0.6487;In 33 cases of patients in stageⅡ, the correction values of AIB-1 expression(AIB-1/GAPDH) was 1.6894±0.7214; In 16 cases of patients in stageⅢ, the correction values of AIB-1 expression (AIB-1/GAPDH) was 1.8409±0.6482. There was no obvious difference in the distribution of clinical stage after statistical analysis (p=0.086).Expression of AIB-1 had no relationship with the clinical stages.3.1.5 The histological grade of the patients were analyzed.In 58 cases of patients in histological gradeⅠ～Ⅱ, the correction values of AIB-1 expression (AIB-1/GAPDH) was 1.6495±0.7298;In 10 cases of patients in histological gradeⅢ, the correction values of AIB-1 expression (AIB-1/GAPDH) was 1.8325±0.7753.There was obvious difference in the distribution of histological grade after statistical analysis(Z=-2.214;p=0.013). Expression of AIB-1 had positive correlation with the histological grades.3.1.6 The metastatic state of the axillary lymph nodes of the patients were analyzed.In 25 cases of patients in negative group, the correction values of AIB-1 expression (AIB-1/GAPDH) was 1.5873±0.6238;In 27 cases of patients in N+<3 group, the correction values of AIB-1 expression (AIB-1/GAPDH) was 1.7609±0.6941;In 16 cases of patients in N+>3 group, the correction values of AIB-1 expression(AIB-1/GAPDH)was 1.8724±0.7853. There was obvious difference in the distribution of metastatic state of the axillary lymph nodes after statistical analysis (p=0.008).Further studies show that there were obvious differences among the groups (Z=-2.526,p=0.004; Z=-2.195, p=0.014;Z=-2.279, p=0.011), Expression of AIB-1 had positive correlation with the metastatic state of the axillary lymph nodes.3.1.7 The pathological type of the patients were analyzed.In 56 cases of patients in invasive ductal carcinoma, the correction values of AIB-1 expression (AIB-1/GAPDH) was 1.6953±0.6824;In 7 cases of patients in invasive lobular carcinoma, the correction values of AIB-1 expression (AIB-1/GAPDH) was1.7159±0.7043; In 5 cases of patients in other types, the correction values of AIB-1 expression (AIB-1/GAPDH) was 1.7351±0.6439. There was no obvious difference in the distribution of pathological type after statistical analysis (p=0.546).Expression of AIB-1 had no relationship with the pathological type.3.2 The relationships between expression of AIB-1 and C-erbB-2,ER,PR on mRNA level3.2.1 The expression of C-erbB-2 protein was analysed.In 18 cases of patients in C-erbB-2 (-) group, the correction values of AIB-1 expression (AIB-1/GAPDH) was 1.5942±0.6953;In 31 cases of patients in C-erbB-2(+)-～(++) group, the correction values of AIB-1 expression (AIB-1/GAPDH) was 1.6803±0.7236;In 19 cases of patients in C-erbB-2 (+++) group, the correction values of AIB-1 expression (AIB-1/GAPDH) was 1.8742±0.7152.There was no obvious difference in the distribution of the expression of C-erbB-2 protein after statistical analysis (p=0.054).Expression of AIB-1 had no relationship with the expression of C-erbB-2 protein.3.2.2 The expression of ER protein was analysed.In 32 cases of patients in ER(+)-(++)group, the correction values of AIB-1 expression(AIB-1/GAPDH) was 1.7653±0.7512;In 36 cases of patients in ER(+++) group, the correction values of AIB-1 expression (AIB-1/GAPDH) was 1.8463±0.8635.There was no obvious difference in the distribution of the expression of ER protein after statistical analysis (Z=-0.976;p=0.573). Expression of AIB-1 had no relationship with the expression of ER protein.3.2.3 The expression of PR protein was analysed.In 44 cases of patients in PR(-)-(++)group,the correction values of AIB-1 expression(AIB-1/GAPDH) was 1.6834±0.6728;In 24 cases of patients in PR(+++) group, the correction values of AIB-1 expression (AIB-1/GAPDH) was 1.7931±0.6826.There was no obvious difference in the distribution of the expression of PR protein after statistical analysis (Z=-0.684;p=0.647).Expression of AIB-1 had no relationship with the expression of PR protein.4 The analysis of AIB-1 expression and the relationship of clinical-pathological characteristics on protein level.4.1 The ages of the patients were analyzed.According to the analysis on the ages of the patients,AIB-1 was hyper-expressed in 11 of 32 patients below 50(34.38%),6 of 36 were hyper-expressed in the patients above 50 (16.67%). There was no obvious difference in the distribution of ages after statistical analysis(x2=2.883;p=0.092). Expression of AIB-1 had no relationship with the distribution of age.4.1.2 The menstrual condition of the patients were analyzed.According to the menstrual condition of the patients,AIB-1 was hyper-expressed in 11 of 34 pre-menopause patients (32.35%),6 of 34 were hyper-expressed in post-menopause patients (17.65%). There was no obvious difference in the distribution of menstrual condition after statistical analysis(χ2=1.961;p=0.161). Expression of AIB-1 had no relationship with the distribution of menstrual condition.4.1.3 The tumor size of the patients were analyzed. According to the tumor size of the patients,AIB-1 was hyper-expressed in 11 of 41 patients in T<2cm group(26.83%),6 of 27 were hyper-expressed in T>2cm group(22.22%). There was no obvious difference in the distribution of tumor size after statistical analysis(χ2=0.184;p=0.668).Expression of AIB-1 had no relationship with the tumor size.4.1.4 The clinical stage of the patients were analyzed. According to analysis on the clinical stage,AIB-1 was hyper-expressed in 4 of 19 patients in stageⅠ(21.05%),and was hyper-expressed in 10 of 33 patients in stageⅡ(30.30%),while 3 of 16 patients in stageⅢ(18.75%)AIB-1 was hyper-expressed.There was no obvious difference in the distribution of clinical stage after statistical analysis (χ2=0.993;p=0.605).Expression of AIB-1 had no relationship with the clinical stages. 4.1.5 The histological grade of the patients were analyzed.According to the analysis on the histological grades,AIB-1 was hyper-expressed in 14 of 58 patients in histological gradeⅠ～Ⅱ(24.14%),and was hyper- expressed in 3 of 10 patients in histological gradeⅢ(30.00%),There was no obvious difference in the distribution of histological grade after statistical analysis(χ2=0.156; p=0.693).Expression of AIB-1 had no relationship with the histological grades.4.1.6 The metastatic state of the axillary lymph nodes of the patients were analyzed.According to the analysis on the metastatic state of the axillary lymph nodes,AIB-1 was hyper-expressed in 3 of 25 patients in negative group(12.00%),and was hyper-expressed in 6 of 27 patients in N+≤3 group(22.22%), while 8 of 16 patients in N+>3 group (50.00%) AIB-1 was hyper-expressed.There was obvious difference in the distribution of metastatic state of the axillary lymph nodes after statistical analysis (χ2=7.346; p=0.025).Expression of AIB-1 had positive correlation with the metastatic state of the axillary lymph nodes.4.1.7 The pathological type of the patients were analyzed.According to the analysis on the pathological type,AIB-1 was hyper-expressed in 13 of 56 patients in invasive ductal carcinoma (23.21%),and was hyper-expressed in 3 of 7 patients in invasive lobular carcinoma (42.86%), while 1 of 5 patients in other types (20.00%) AIB-1 was hyper-expressed.There was no obvious difference in the distribution of pathological type after statistical analysis (χ2=1.225;p=0.542).Expression of AIB-1 had no relationship with the pathological type.4.2 The relationships between expression of AIB-1 and C-erbB-2,ER,PR on protein level4.2.1 The expression of C-erbB-2 protein was analysed.According to the analysis on the expression of C-erbB-2 protein,AIB-1 was hyper-expressed in 2 of 18 patients in C-erbB-2 (-) group (11.11%),and was hyper-expressed in 5 of 31 patients in C-erbB-2(+)-(++) group (16.12%), while 10 of 19 patients in C-erbB-2 (+++) group (52.63%) AIB-1 was hyper-expressed.There was obvious difference in the distribution of the expression of C-erbB-2 protein after statistical analysis (χ2=10.241;p=0.006).Expression of AIB-1 had positive correlation with the expression of C-erbB-2 protein.4.2.2 The expression of ER protein was analysed.According to the analysis on the expression of ER protein,AIB-1 was hyper-expressed in 11 of 32 patients in ER(+)-(++) group(34.38%),and was hyper-expressed in 6 of 36 patients in ER(+++) group (16.67%).There was no obvious difference in the distribution of the expression of ER protein after statistical analysis(χ2=2.833; p=0.092).Expression of AIB-1 had no relationship with the expression of ER protein.4.2.3 The expression of PR protein was analysed.According to the analysis on the expression of PR protein,AIB-1 was hyper-expressed in 10 of 44 patients in PR(-)～(++) group(28.57%),and was hyper-expressed in 6 of 24 patients in PR(+++)group(25.00%).There was no obvious difference in the distribution of the expression of PR protein after statistical analysis(x2=0.343;p=0.558). Expression of AIB-1 had no relationship with the expression of PR protein. 5 Relationship between the expression of PAX2 and AIB-1 on protein level.PAX2 was hyper-expressed in 18 of 51 patients in AIB-1 (-)～(++) group (35.29%), and was hyper-expressed in 1 of 17 patients in AIB-1 (+++) group (5.88%).There was obvious difference in the distribution of the expression of AIB-1 protein after statistical analysis(x2=4.115;p=0.043;r=-0.422).Expression of PAX2 had negative correlation with the expression of AIB-1 protein.Conclusion:1 The expression of PAX2 has no significant relationship between tumor tissues and normal breast tissues on mRNA level.Expression of PAX2 has no significant relationship with age,menses,tumor size, clinical stage,histology grade,metastatic state of the axillary lymph nodes,pathology type and the expression of ER,PR on mRNA level and protein level.2 The expression of AIB-1 in the tumor tissues are higher than that of the normal breast tissues on mRNA level.Expression of AIB-1 has positive correlation with the histology grade but has no correlation on protein level. Expression of AIB-1 has positive correlation with the metastatic state of the axillary lymph nodes both on protein level and mRNA level,AIB-1 has no significant relationship with age,menses,tumor size, clinical stage,pathology type and the expression of ER,PR.3 PAX2 is negatively correlated with C-erbB-2 both on protein level and mRNA level;AIB-1 is positively correlated with C-erbB-2 on protein level but not on mRNA level;PAX2 is negatively correlated with AIB-1.We conclude that the quantitative relationship between PAX2 and AIB-1 indicates the expression of C-erbB-2,futher indicates that the quantitative relationship between PAX2 and AIB-1 is an important index for resistance to anti-estrogen therapy of ER-positive breast cancer patients.